GlobeNewswire

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
11/05/2026
DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT ) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business [...]
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
11/05/2026
BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 20, 2026, to [...]
Amwell® to Participate in Upcoming Investor Conference
11/05/2026
BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced that Mark Hirschhorn, CFO and COO, [...]
Health Catalyst Reports First Quarter 2026 Results
11/05/2026
SALT LAKE CITY, May 11, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today [...]
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
11/05/2026
Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026 Continued execution across the oncology pipeline, with a strategic focus on three priority [...]
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
11/05/2026
Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened balance [...]
ArriVent BioPharma Reports First Quarter 2026 Financial Results
11/05/2026
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026 IND clearance of ARR-002, ArriVent’s dual-targeting MUC16/NaPi2b tetravalent ADC, advances into [...]
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
11/05/2026
Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segments Initiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); [...]
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
11/05/2026
Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chronic, symptomatic [...]
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
11/05/2026
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Phase 1 Clinical Trial Initiated for SEP-479 [...]
Erasca Reports First Quarter 2026 Business Updates and Financial Results
11/05/2026
Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted agents ERAS- [...]
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
11/05/2026
CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2 Engaged Lilly Catalyze360 to provide [...]
Portsmouth Square, Inc. Reports Third Quarter Fiscal 2026 Results; Hotel Operating Results Improve Year‑Over‑Year as San Francisco Recovery Progresses
11/05/2026
Los Angeles, California, May 11, 2026 (GLOBE NEWSWIRE) -- Portsmouth Square, Inc. (the “Company” or “Portsmouth”) today announced financial results for the fiscal third quarter ended March 31, 2026. Portsmouth’s [...]
GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents
11/05/2026
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 11, 2026 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life- [...]
GENFIT : Assemblée Générale Mixte du 15 juin 2026 — modalités de mise à disposition des documents préparatoires
11/05/2026
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 11 mai 2026 – GENFIT (Euronext: GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares [...]
Lumenis Stellar M22™ with XPL Technology Named “Best New Dermatology Technology Solution” in 2026 MedTech Breakthrough Awards Program
11/05/2026
Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Technology Solutions Worldwide LOS ANGELES, May 11, 2026 (GLOBE NEWSWIRE) -- MedTech Breakthrough , an independent market [...]
Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox Vaccines
11/05/2026
Exercised options total USD 97 million, covering manufacturing of bulk vaccine and supply of freeze-dried vaccines. Company upgrades full-year financial guidance COPENHAGEN, Denmark, May 11, 2026 – Bavarian Nordic A/S ( [...]
Fagron shareholders approve all proposed resolutions at the General Meetings
11/05/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 11 May 2026 – 6PM CET Fagron shareholders approve all proposed resolutions at the General Meetings Fagron, the leading global player in [...]
IBA – ACQUISITION OF OWN SHARES
11/05/2026
Louvain-la-Neuve, Belgium, May 11 th , 2026 – 6 PM CEST – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum